Irena Konstantinova
Head of Biology FoRx Therapeutics AG
Seminars
Thursday 29th January 2026
Advancing PARG Inhibition: From Preclinical Rationale to Early Clinical Development
1:30 pm
• See how FoRx Therapeutics is progressing PARG inhibition with FORX-428 to differentiate from other DDR targets
• Positioning FORX-428 as a best-in-class candidate for PARG inhibition in cancer treatment
• Updating on the translational research activities and biomarker identification for patient selection in the ongoing phase I clinical study of FORX-428
